Immunization Update

Ongoing Work and Future Roadmap

Alison Tickle Kemeny, Solutions Manager EHR

December 15, 2021



Agenda


COVID-19 Vaccines

Spring 2021

Ongoing Development

Future Roadmap





COVID-19 Vaccines

Takeaways and Learnings

- Industry use of existing requirements for codification patterns
- Communication efforts across departments and agencies was key
- Adaptability of Immunization Registries and programs across the country
- Rapid changes sometimes hard to adjust to on the technology side (e.g. state requirement fluctuations)
- Impacts and challenges of clinical recommendations changing and evolving


For NextGen clients: System configurability was essential

- Use of existing Medication Update process to deliver vaccine content
- Use of peripheral solutions to meet organization needs



COVID-19 Vaccines - Ongoing Efforts

- Moderna Booster Same CVX 207, Different CPT code
 - No Lot Number differentiation in Vaccine Details (KI198612)
 - Patch for Spring 2021 version expected December 2021
 - Patches for prior versions expected January 2022
 - Workaround suggestion use capitalized letters vs. non-capitalized as differentiator





COVID-19 Vaccines - Ongoing Efforts

- Pfizer Pediatric doses Included in November Medication update
 - Delay getting content from FDB that contained vaccine CPT codes (KI198587)
 - Pediatric Precaution DUR alert still showing even with pediatric approval (KI198658)
 - FDB has resolved this, change should be included in December Medication update
- Vaccine Administrators Guide updated
 - Expected on Success Community December 2021



COVID-19 Vaccines - Challenges


- Immunization Registry Reporting Accuracy
 - Current industry issue: Incorrect CVX being reported on pediatric aged patients
 - Solution: Ensure Vaccine Inventory setup correctly to differentiate pediatric and adult Pfizer doses (CVX 208 vs. 218)
 - Note: CVX 217 (Adult tri-sucrose formulation not on the market yet) should not be used
- Administrative Coding
 - Use of CPT codes to report dose number technical challenge
- Forecasting and Recommendations
 - How big of a need is this?
- You Tell Us...What other challenges should we be aware of?






Spring 2021 – Immunizations in Order Entry

Workflow Comparison – Immunization Module





Visual Comparison – Order Entry







Ongoing Development

- Immunization Recommendations and Forecasting updates by Vaccine Group (KI194737)
 - **HPV** add dose 2 recommendation if dose 1 given early (KI166544)
 - Tdap includes catch-up rules for 7 years and up (KI193905 and KI196877)
 - Pediarix valid 4 doses of Hep B (KI150016)
 - Pneumococcal Adult PPSV default recommendation and logic changes (KI194295)
 - Meningococcal updated recommendations if given early
 - Meningitis B -- "recommendation" changes



Future Release Roadmap

Forecasting

External Rules
 Engine as an
 Enterprise
 Service (IDEA 2488)



Inventory and Reporting Accuracy

- Enhanced Stock support (IDEA-1727 and IDEA-2417)
- VFC Age
 Configuration
 (IDEA-12703 and IDEA-9392)

Usability

 Vaccine Inventory improvements – interactions and display





Future Release Roadmap

Immunization Registry

- Consent configurability additions for documenting and reporting
- Reporting of contraindications and reactions in HL7
- Automated query(s) for history and forecast (single patients or in bulk)

Reporting

 Track patients' by vaccine status – due or overdue



Additional Needs

 You Tell Us...What other challenges should we be aware of?





BELIEVE IN BETTER.®





LEGAL NOTICE: This document contains information that is confidential and proprietary to NextGen Healthcare, Inc. and its subsidiaries and affiliates ("Company") and is intended for use solely by its authorized clients or partners. This document may not be copied, reproduced, published, displayed, otherwise used, transmitted, or distributed in any form by any means as a whole or in any part, nor may any of the information it contains be used or stored in any information retrieval system or media, translated into another language, or otherwise made available or used by anyone other than the authorized client or partner to whom this document was originally delivered without the prior, written consent of Company.

By retaining or using this document, you represent that you are a party who is authorized to use this document under one or more agreements between you and Company now in force, and that you will use this document and the information it contains solely as and to the extent such agreement(s) permit. If there is no agreement in place between the parties, you represent that you are the intended recipient of this document and that you will at a minimum, hold any confidential or proprietary information it contains to the same standards you would hold information from your own organization. Any other use or distribution of the contents of this document, as a whole or in any part, is prohibited.

Although we exercised great care in creating this publication, Company assumes no responsibility for errors or omissions that may appear in this publication and reserves the right to change this publication at any time without notice.

© 2021 NXGN Management, LLC. All Rights Reserved.

The registered trademarks listed at www.nextgen.com/legal-notice are the registered trademarks of NXGN Management, LLC. All other names and marks are the property of their respective owners.

Our issued and published patents can be found at www.nextgen.com/legal-notice.

